[
  {
    "objectID": "slides/ACUTE_SLIDES.html#adapting-bloodculture-systems-to-monitor-antimicrobial-efficacy",
    "href": "slides/ACUTE_SLIDES.html#adapting-bloodculture-systems-to-monitor-antimicrobial-efficacy",
    "title": "The Acute Website",
    "section": "Adapting Bloodculture Systems to Monitor Antimicrobial Efficacy",
    "text": "Adapting Bloodculture Systems to Monitor Antimicrobial Efficacy\n\n\n\n\n\n\nPrinciple Investigator: Irene Zaghi, M.D.\nSupervisors:\n\nRussell E. Lewis, Pharm.D., University of Padua\nMonica Cricca, M.D., Ph.D., University of Bologna\nVittorio Sambri, M.D., Ph.D., Univeristy of Bologna\n\n\n\nJanuary 20, 2023"
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#antibiotic-dosing-is-an-uncertain-science",
    "href": "slides/ACUTE_SLIDES.html#antibiotic-dosing-is-an-uncertain-science",
    "title": "The Acute Website",
    "section": "Antibiotic dosing is an uncertain science",
    "text": "Antibiotic dosing is an uncertain science\n\n\n\n\n\n\n\nImage: Irene Zaghi, M.D."
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#antibiotic-dosing-is-an-uncertain-science-1",
    "href": "slides/ACUTE_SLIDES.html#antibiotic-dosing-is-an-uncertain-science-1",
    "title": "The Acute Website",
    "section": "Antibiotic dosing is an uncertain science",
    "text": "Antibiotic dosing is an uncertain science\n\n\n\n\n\n\n\n\n(Theuretzbacher 2012; Roberts et al. 2014)"
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#antibiotic-dosing-is-an-uncertain-science-2",
    "href": "slides/ACUTE_SLIDES.html#antibiotic-dosing-is-an-uncertain-science-2",
    "title": "The Acute Website",
    "section": "Antibiotic dosing is an uncertain science",
    "text": "Antibiotic dosing is an uncertain science\n\n\n\n\n\n\n\n\n(Theuretzbacher 2012; Roberts et al. 2014)"
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#how-can-dosing-uncertainty-be-managed",
    "href": "slides/ACUTE_SLIDES.html#how-can-dosing-uncertainty-be-managed",
    "title": "The Acute Website",
    "section": "How can dosing uncertainty be managed?",
    "text": "How can dosing uncertainty be managed?\n\n\n\n\n\n\n\n(Roberts et al. 2014)"
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#dosing-uncertainty-at-the-dawn-of-penicillin-resistance",
    "href": "slides/ACUTE_SLIDES.html#dosing-uncertainty-at-the-dawn-of-penicillin-resistance",
    "title": "The Acute Website",
    "section": "Dosing uncertainty at the dawn of penicillin resistance",
    "text": "Dosing uncertainty at the dawn of penicillin resistance\n\n\n\n\n\n\n\n(Schlichter and Mac Lean 1947)"
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#dosing-uncertainty-at-the-dawn-of-penicillin-resistance-1",
    "href": "slides/ACUTE_SLIDES.html#dosing-uncertainty-at-the-dawn-of-penicillin-resistance-1",
    "title": "The Acute Website",
    "section": "Dosing uncertainty at the dawn of penicillin resistance",
    "text": "Dosing uncertainty at the dawn of penicillin resistance\n\n\n\n“It was felt that there was a need of some definite basis for determining adequate therapy for each specific infectious organism involved…”\n\n\n“Current methods in general use all depend on indirect comparisons (MICs, measurement of penicillin blood levels). In patients with more resistant organisms, it has not been demonstrated that this is the proper approach…”\n\n\n“…It occurred to us that a more satisfactory method of outlining adequate therapy in resistant organisms might be based on the action of the patient’s own serum during penicillin administration.”\n\n\n\n(Schlichter and Mac Lean 1947)"
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#serum-bactericidal-test-sbt",
    "href": "slides/ACUTE_SLIDES.html#serum-bactericidal-test-sbt",
    "title": "The Acute Website",
    "section": "Serum bactericidal test (SBT)",
    "text": "Serum bactericidal test (SBT)\n\n\n\n\n\n\n\n(CLSI 1999; Zaghi et al. 2020)"
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#sbts-correlate-with-antibiotic-pkpd",
    "href": "slides/ACUTE_SLIDES.html#sbts-correlate-with-antibiotic-pkpd",
    "title": "The Acute Website",
    "section": "SBTs correlate with antibiotic PK/PD",
    "text": "SBTs correlate with antibiotic PK/PD\n\n\n\n\n\n\n\n(Zaghi et al. 2020)"
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#potential-clinical-utility-of-sbts",
    "href": "slides/ACUTE_SLIDES.html#potential-clinical-utility-of-sbts",
    "title": "The Acute Website",
    "section": "Potential clinical utility of SBTs",
    "text": "Potential clinical utility of SBTs\nIndividual patient-level diagnostic meta-analysis (1947-2020)\n\n\n\n\n\nPrognostic performance similar or better than current susceptibility breakpoints\n\n\n(Zaghi et al. 2020)"
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#sbt-advantages",
    "href": "slides/ACUTE_SLIDES.html#sbt-advantages",
    "title": "The Acute Website",
    "section": "SBT advantages",
    "text": "SBT advantages\n\n\nOnly microbiological test that accounts for both antibiotic PK and PD\nAccounts for protein binding changes\nCan detect synergistic or antagonistic antibiotic interactions"
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#why-were-sbts-abandoned",
    "href": "slides/ACUTE_SLIDES.html#why-were-sbts-abandoned",
    "title": "The Acute Website",
    "section": "Why were SBTs abandoned?",
    "text": "Why were SBTs abandoned?\n\n\nInsufficient standardization despite published methods\n\nCLSI M21-A, last updated 1999\n\nPoor inter-laboratory reproducibility\nLabour-intensive to perform\nLack of perceived need after introduction of reliably bactericidal antibiotics in 1990s\n\n3rd generation cephalosporins, fluoroquinolones, carbapenems\n\nDelay in results reporting (48-72 hours with patients isolate)"
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#i-read-your-sbt-review-and-have-a-suggestion",
    "href": "slides/ACUTE_SLIDES.html#i-read-your-sbt-review-and-have-a-suggestion",
    "title": "The Acute Website",
    "section": "“I read your SBT review and have a suggestion…”",
    "text": "“I read your SBT review and have a suggestion…”\nUse continuously-monitored bloodculture systems Time-to-positivity (Tpos) to measure bactericidal activity\nConcept: The assay will measure time taken for a standardized bacterial inoculum to “grow through” the antimicrobial activity in the patient’s serum under defined conditions.\n\n\n\n\n\n\n\n\nA short Tpos would indicate inadequate antimicrobial activity and should predict a worse outcome\nA long Tpos is evidence of adequate antimicrobial activity and should predict a good outcome"
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#blood-culture-tpos-measures-bacterial-inoculum-and-antimicrobial-pharmacokinetics",
    "href": "slides/ACUTE_SLIDES.html#blood-culture-tpos-measures-bacterial-inoculum-and-antimicrobial-pharmacokinetics",
    "title": "The Acute Website",
    "section": "Blood culture Tpos measures bacterial inoculum and antimicrobial pharmacokinetics",
    "text": "Blood culture Tpos measures bacterial inoculum and antimicrobial pharmacokinetics\n\n\nA “critical” Tpos result could be reported in < 12 hours!\n\n\n\n\n\n\n\n\n(Kaltsas, Want, and Cohen 2005; Jerwood, Hankins, and Cohen 2012)"
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#adapting-bloodculture-systems-to-monitor-antimicrobial-efficacy-1",
    "href": "slides/ACUTE_SLIDES.html#adapting-bloodculture-systems-to-monitor-antimicrobial-efficacy-1",
    "title": "The Acute Website",
    "section": "Adapting Bloodculture Systems to Monitor Antimicrobial Efficacy",
    "text": "Adapting Bloodculture Systems to Monitor Antimicrobial Efficacy\n\n\n\n\nSpecific Aim# 1: Establish the quantitative relationship in vitro between Tpos and carbapenamase-producing Enterobacterales (CPE) and define antibiotic concentration-effect relationships\nSpecific Aim#2: Pilot observational clinical study in 20 septic patients undergoing treatment for CPE to explore how early Tpos results with “indicator” isolates correlate with individual antibiotic PK/PD targets"
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#tpos-correlates-with-inoculum",
    "href": "slides/ACUTE_SLIDES.html#tpos-correlates-with-inoculum",
    "title": "The Acute Website",
    "section": "Tpos correlates with inoculum",
    "text": "Tpos correlates with inoculum\n\nK. pneumoniaeE. coliA. baumaniiP. aeruginosa\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nR2 = 0.96-0.99"
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#tpos-can-descriminate-between-susceptible-and-resistant-pathogens",
    "href": "slides/ACUTE_SLIDES.html#tpos-can-descriminate-between-susceptible-and-resistant-pathogens",
    "title": "The Acute Website",
    "section": "Tpos can descriminate between susceptible and resistant pathogens",
    "text": "Tpos can descriminate between susceptible and resistant pathogens\n\n\n\n\n\n\n\nKPC_B MIC 1.0 mg/L, KPC_NDM MIC > 256 mg/L; data fit by Loess"
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#pharmacodynamic-relationship-of-tpos-against-k.-pneumoniae-atcc-700603-0.75-mgl",
    "href": "slides/ACUTE_SLIDES.html#pharmacodynamic-relationship-of-tpos-against-k.-pneumoniae-atcc-700603-0.75-mgl",
    "title": "The Acute Website",
    "section": "Pharmacodynamic relationship of Tpos against  K. pneumoniae ATCC 700603 (0.75 mg/L)",
    "text": "Pharmacodynamic relationship of Tpos against  K. pneumoniae ATCC 700603 (0.75 mg/L)\n\nCeftazidime-avibactam4:1 ratioFixed 4 mg/L\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n  \n      \n    Estimate \n    Lower .95 \n    Upper .95 \n  \n \n\n  \n    0.1 \n    23.87874 \n    19.31716 \n    28.44033 \n  \n  \n    0.25 \n    26.93812 \n    24.06902 \n    29.80723 \n  \n  \n    0.5 \n    30.38948 \n    29.11007 \n    31.66888 \n  \n  \n    0.75 \n    34.28302 \n    31.38838 \n    37.17767 \n  \n  \n    0.9 \n    38.67541 \n    33.84814 \n    43.50268 \n  \n  \n    0.95 \n    41.98020 \n    33.98412 \n    49.97627 \n  \n\n\n\n\n\n\n\n\n\n\n\n \n  \n      \n    Estimate \n    Lower .95 \n    Upper .95 \n  \n \n\n  \n    0.1 \n    8.099087 \n    7.038485 \n    9.159689 \n  \n  \n    0.25 \n    9.235833 \n    8.728989 \n    9.742676 \n  \n  \n    0.5 \n    10.532127 \n    10.149119 \n    10.915134 \n  \n  \n    0.75 \n    12.010361 \n    10.856802 \n    13.163921 \n  \n  \n    0.9 \n    13.696074 \n    11.685276 \n    15.706872 \n  \n  \n    0.95 \n    14.975851 \n    12.415855 \n    17.535846"
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#inoculum-effects-observed-with-pd-relationship-measured-by-tpos",
    "href": "slides/ACUTE_SLIDES.html#inoculum-effects-observed-with-pd-relationship-measured-by-tpos",
    "title": "The Acute Website",
    "section": "Inoculum effects observed with PD relationship measured by Tpos",
    "text": "Inoculum effects observed with PD relationship measured by Tpos"
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#tpos-demonstrates-a-consistent-relationship-across-different-antibiotics-and-isolates-with-different-mics",
    "href": "slides/ACUTE_SLIDES.html#tpos-demonstrates-a-consistent-relationship-across-different-antibiotics-and-isolates-with-different-mics",
    "title": "The Acute Website",
    "section": "Tpos demonstrates a consistent relationship across different antibiotics and isolates with different MICs",
    "text": "Tpos demonstrates a consistent relationship across different antibiotics and isolates with different MICs"
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#comparison-of-indicator-isolates",
    "href": "slides/ACUTE_SLIDES.html#comparison-of-indicator-isolates",
    "title": "The Acute Website",
    "section": "Comparison of indicator isolates",
    "text": "Comparison of indicator isolates\n\nFigure 1: Pharmacodynamic relationship of Tpos to ceftazidime/avibactam concentrations"
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#combination-therapy",
    "href": "slides/ACUTE_SLIDES.html#combination-therapy",
    "title": "The Acute Website",
    "section": "Combination therapy",
    "text": "Combination therapy"
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#ceftazidime-avibactam-gentamicin",
    "href": "slides/ACUTE_SLIDES.html#ceftazidime-avibactam-gentamicin",
    "title": "The Acute Website",
    "section": "Ceftazidime-avibactam + gentamicin",
    "text": "Ceftazidime-avibactam + gentamicin"
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#how-could-tpos-be-used-clinically",
    "href": "slides/ACUTE_SLIDES.html#how-could-tpos-be-used-clinically",
    "title": "The Acute Website",
    "section": "How could Tpos be used clinically",
    "text": "How could Tpos be used clinically"
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#could-tpos-be-performed-with-indicator-isolates",
    "href": "slides/ACUTE_SLIDES.html#could-tpos-be-performed-with-indicator-isolates",
    "title": "The Acute Website",
    "section": "Could Tpos be performed with “indicator” isolates?",
    "text": "Could Tpos be performed with “indicator” isolates?"
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#references",
    "href": "slides/ACUTE_SLIDES.html#references",
    "title": "The Acute Website",
    "section": "References",
    "text": "References\n\n\n\n\n\n\n\nCLSI. 1999. Methodology for the Serum Bactericidal Test; Approved Guideline M21-A.\n\n\nJerwood, Susannah, Matthew Hankins, and Jon Cohen. 2012. “A Pilot Clinical Trial to Evaluate a Novel Time-to-Positivity Assay to Measure the Effectiveness of Antibiotic Therapy for Septic Patients in Intensive Care.” Journal of Critical Care 27 (3): 320.e1–5. https://doi.org/10.1016/j.jcrc.2011.06.009.\n\n\nKaltsas, P, S Want, and J Cohen. 2005. “Development of a Time-to-Positivity Assay as a Tool in the Antibiotic Management of Septic Patients.” Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases 11 (2): 109–14. https://doi.org/10.1111/j.1469-0691.2004.01054.x.\n\n\nRoberts, Jason A, Mohd H Abdul-Aziz, Jeffrey Lipman, Johan W Mouton, Alexander A Vinks, Timothy W Felton, William W Hope, et al. 2014. “Individualised Antibiotic Dosing for Patients Who Are Critically Ill: Challenges and Potential Solutions.” The Lancet Infectious Diseases 14 (6): 498–509. https://doi.org/10.1016/s1473-3099(14)70036-2.\n\n\nSchlichter, J. G., and H. Mac Lean. 1947. “A Method of Determining the Effective Therapeutic Level in the Treatment of Subacute Bacterial Endocarditis with Penicillin; a Preliminary Report.” American Heart Journal 34 (2): 209–11. https://doi.org/10.1016/0002-8703(47)90289-5.\n\n\nTheuretzbacher, Ursula. 2012. “Pharmacokinetic and Pharmacodynamic Issues for Antimicrobial Therapy in Patients with Cancer.” Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 54 (12): 1785–92. https://doi.org/10.1093/cid/cis210.\n\n\nZaghi, I., P. Gaibani, C. Campoli, M. Bartoletti, M. Giannella, S. Ambretti, P. Viale, and R. E. Lewis. 2020. “Serum Bactericidal Titres for Monitoring Antimicrobial Therapy: Current Status and Potential Role in the Management of Multidrug-Resistant Gram-negative Infections.” Clinical Microbiology and Infection 26 (10): 1338–44. https://doi.org/10.1016/j.cmi.2020.04.036."
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#tpos-can-discriminate-between-susceptible-and-resistant-pathogens",
    "href": "slides/ACUTE_SLIDES.html#tpos-can-discriminate-between-susceptible-and-resistant-pathogens",
    "title": "The Acute Website",
    "section": "Tpos can discriminate between susceptible and resistant pathogens",
    "text": "Tpos can discriminate between susceptible and resistant pathogens\n\n\n\n\n\n\n\nKPC_B MIC 1.0 mg/L, KPC_NDM MIC > 256 mg/L; data fit by Loess"
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#comparison-of-k.-pneumoniae-indicator-isolates",
    "href": "slides/ACUTE_SLIDES.html#comparison-of-k.-pneumoniae-indicator-isolates",
    "title": "The Acute Website",
    "section": "Comparison of K. pneumoniae indicator isolates",
    "text": "Comparison of K. pneumoniae indicator isolates"
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#at-a-standardized-inoculum-tpos-demonstrates-a-consistent-relationship-across-different-antibiotics-and-isolates-with-different-mics",
    "href": "slides/ACUTE_SLIDES.html#at-a-standardized-inoculum-tpos-demonstrates-a-consistent-relationship-across-different-antibiotics-and-isolates-with-different-mics",
    "title": "The Acute Website",
    "section": "At a standardized inoculum, Tpos demonstrates a consistent relationship across different antibiotics and isolates with different MICs",
    "text": "At a standardized inoculum, Tpos demonstrates a consistent relationship across different antibiotics and isolates with different MICs"
  }
]